At the Forefront of Targeted Cancer Therapies

Developing the next generation of medications for the treatment of cancers and genetic diseases

Patient Focused

Focused Research & Development with patients in mind

Experienced Team

Dedicated to the next generation of targeted therapies

Personalised Medicine

The cutting edge of targeting cancer & genetic diseases

Active Clinical Development Programs

PIQUR Half Image topical and oral

Bimiralisib’s oral and topical formulations are under clinical development for the treatment of Head and Neck Squamous Cell Carcinoma (oral) and Cutaneous T-Cell Lymphoma (topical).

In addition, PIQUR has several other compounds in preclinical research in oncology, dermatology, CNS disorders and genetic diseases.

Clinical Development

clinical development v4

Pre-clinical

pipeline

Partners

To fully exploit the potential of our drug candidates, we welcome strategic partnerships with renowned biotech and pharmaceutical companies.

PIQUR Narrow Half Image partners

Investors

PIQUR Therapeutics AG is a privately owned company backed by private investors and Versant Venture, a leading venture capital firm.

PIQUR Half Image invesment
PIQUR Half Image careers

Career Development

We are always looking to develop our team.  Our location and facilities are an ideal place for you to be at the forefront of cancer therapy discoveries.